- Category
- Small (2024-25)
- Udyam number
- UDYAM-MH-33-0082699

About Clinitech Laboratory Limited
Data last updated:
Clinitech Laboratory Limited is a public limited company based in Navi Mumbai, Maharashtra, India. It operates in the diagnostic centers and pathology labs segment of the healthcare sector. It was incorporated on 19 March 2010 and has been in existence for over 16 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L85195MH2010PLC201078. It is a listed company as per MCA records. Its shares are listed on BSE: 544220.
The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹2.28 Cr. It is led by directors including Jagdish Umakant Nayak (Managing Director) and Jyoti Jagdish Nayak (Whole-Time Director).
Its last annual general meeting (AGM) was held on 23 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Al – 1/545 Sector 16 Airoli Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Maharashtra, India – 400708.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹9.49 Cr, a growth of 15.3% compared to the previous year. For the same year it recorded a net profit of ₹43 Lakh (net margin 4.5%) and EBITDA of ₹1 Cr (EBITDA margin 10.5%). The net worth stands at ₹9.25 Cr (up 4.8% YoY). Total assets are valued at ₹10.04 Cr (up 11.2% YoY).
The company has about 13 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Clinitech Laboratory. As per MCA filings, the company has open charges of ₹1.02 Cr and satisfied charges of ₹1.22 Cr on record. Court records list 1 case involving the company, including 1 filed by the company; 1 case is pending. The company has 17 deals on record (15 market trades, 1 ipo, 1 funding round), with disclosed funding of ₹68.4 Lakh; the latest was in April 2026. The company has 4 MSME Form 1 returns on record between 2019 and 2024, listing 39 overdue payments to 9 micro and small suppliers.
Clinitech Laboratory Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-33-0082699). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website ctllab.in.
Company details
CIN history
Clinitech Laboratory has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L85195MH2010PLC201078, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L85195MH2010PLC201078 | Current |
| U85195MH2010PLC201078 | Previous |
| U85195MH2010PTC201078 | Previous |
Recognitions & Rankings of Clinitech Laboratory
Contact details
Clinitech Laboratory Limited's registered office is in Navi Mumbai, Maharashtra.
- Social Media
- Registered AddressAl – 1/545 Sector 16 Airoli Opposite Radhikabai Meghe Vidyalaya, Navi Mumbai, Maharashtra, India – 400708
- IndustryHealthcare, Diagnostic Centers & Pathology Labs
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Clinitech Laboratory operates one associated brand: Clinitech Laboratory. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pathology lab services are operated through a chain in India. | clinitechlab.com |
Business activity
The main business activity of Clinitech Laboratory is hospital and medical care. In detail, this covers medical and dental practice, nursing, pathology, blood bank services, etc..
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| Q | Hospital and Medical Care | Q2 | Medical and dental practice, Nursing, pathology, blood bank services, etc. |
To see the full business activity and turnover split of Clinitech Laboratory Limited, buy the company report.
Financials of Clinitech Laboratory Limited
FY 2025-26 filings availableClinitech Laboratory Limited reported revenue of ₹9.49 Cr (up 15.3% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Income statement | ||
| Revenue | 9.49 | 8.23 |
| Revenue growth | +15.3% | - |
| EBITDA | 1.00 | 0.82 |
| EBITDA margin | +10.5% | +10.0% |
| Profit before tax | 0.61 | 0.54 |
| Net profit | 0.43 | 0.29 |
| Net profit margin | +4.5% | +3.5% |
| EPS (₹) | 1.83 | 1.73 |
| Balance sheet | ||
| Total assets | 10.04 | 9.03 |
| Net worth | 9.25 | 8.83 |
| Total debt | 0.54 | 0.00 |
| Cash & bank | 2.11 | 3.07 |
| Net working capital | 6.23 | 5.65 |
| Cash flow | ||
| Cash from operations | (0.79) | (0.88) |
| Cash from investing | (0.68) | (0.73) |
| Cash from financing | 0.51 | 3.98 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 9.48 | 8.23 | 6.40 | 6.35 | 6.38 | 4.55 |
| Revenue growth | +15.2% | +28.6% | +0.8% | -0.5% | +40.2% | - |
| EBITDA | 1.00 | 0.82 | 1.00 | 1.36 | 1.06 | 0.83 |
| EBITDA margin | +10.6% | +10.0% | +15.6% | +21.4% | +16.6% | +18.2% |
| Profit before tax | 0.61 | 0.54 | 0.51 | 0.86 | 0.69 | 0.54 |
| Net profit | 0.43 | 0.29 | 0.37 | 0.61 | 0.50 | 0.37 |
| Net profit margin | +4.5% | +3.5% | +5.8% | +9.6% | +7.8% | +8.1% |
| EPS (₹) | 1.85 | 1.73 | 2.21 | 4.09 | 3.42 | 6.04 |
| Balance sheet | ||||||
| Total assets | 9.86 | 9.03 | 4.61 | 5.02 | 2.85 | 2.02 |
| Net worth | 9.25 | 8.83 | 3.55 | 2.38 | 1.85 | 1.39 |
| Total debt | 0.36 | 0.00 | 0.87 | 1.03 | 0.89 | 0.54 |
| Cash & bank | 2.06 | 3.07 | 0.70 | 0.78 | 0.10 | 0.32 |
| Net working capital | 6.31 | 5.65 | 1.70 | 0.95 | 0.55 | 0.92 |
| Cash flow | ||||||
| Cash from operations | (0.90) | (0.88) | (1.28) | 1.25 | 0.96 | 0.38 |
| Cash from investing | (0.44) | (0.73) | 0.75 | (0.65) | (1.47) | 0.54 |
| Cash from financing | 0.33 | 3.98 | 0.45 | 0.09 | 0.29 | (0.88) |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Revenue | 9.49 | 8.23 |
| Revenue growth | +15.3% | - |
| Other income | 0.19 | 0.23 |
| Total expenses | 8.49 | 7.41 |
| Employee cost | 2.60 | 2.38 |
| EBITDA | 1.00 | 0.82 |
| EBITDA margin | +10.5% | +10.0% |
| Depreciation | 0.51 | 0.45 |
| Interest | 0.07 | 0.06 |
| Profit before tax | 0.61 | 0.54 |
| Tax | 0.18 | 0.16 |
| Net profit | 0.43 | 0.29 |
| Net profit margin | +4.5% | +3.5% |
| EPS (₹) | 1.83 | 1.73 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Equity & liabilities | ||
| Share capital | 2.28 | 2.28 |
| Reserves & surplus | 6.97 | 6.55 |
| Shareholders' funds (net worth) | 9.25 | 8.83 |
| Minority interest | 0.00 | 0.00 |
| Secured loans | 0.54 | 0.00 |
| Unsecured loans | 0.00 | 0.00 |
| Total debt | 0.54 | 0.00 |
| Total liabilities | 10.04 | 9.03 |
| Assets | ||
| Gross block | 5.90 | 5.33 |
| Net block | 2.18 | 2.12 |
| Capital work in progress | 1.25 | 1.01 |
| Investments | 0.07 | 0.07 |
| Inventories | 0.73 | 0.53 |
| Sundry debtors | 1.85 | 1.54 |
| Cash & bank balances | 2.11 | 3.07 |
| Loans & advances | 2.68 | 2.32 |
| Total current assets | 7.37 | 7.46 |
| Total current liabilities | 1.14 | 1.81 |
| Net working capital | 6.23 | 5.65 |
| Total assets | 10.04 | 9.03 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Opening cash | 3.07 | 0.70 |
| Net cash from operating activities | (0.79) | (0.88) |
| Net cash from investing activities | (0.68) | (0.73) |
| Net cash from financing activities | 0.51 | 3.98 |
| Net change in cash | (0.96) | 2.37 |
| Closing cash | 2.11 | 3.07 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Growth | ||
| Sales growth | +15.3% | - |
| EBITDA growth | +22.0% | - |
| PBT growth | +13.0% | +9997.0% |
| Net income growth | +48.3% | - |
| Profitability & leverage | ||
| Net income margin | +4.5% | +4.6% |
| Return on capital employed | +6.9% | +6.0% |
| Return on net worth | +4.5% | +3.4% |
| Debt / equity | 0.03 | 0.00 |
| Long-term debt / equity | 0.03 | 0.00 |
| Interest cover | 14.29 | 16.22 |
| Efficiency & per share | ||
| Fixed asset turnover | 1.69 | 1.54 |
| Inventory turnover | 15.06 | 15.53 |
| Debtors turnover | 5.60 | 5.34 |
| EPS (₹) | 1.83 | 1.73 |
| Dividend per share (₹) | 0.00 | 0.00 |
| Book value per share (₹) | 40.52 | 38.69 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 9.48 | 8.23 | 6.40 | 6.35 | 6.38 | 4.55 |
| Revenue growth | +15.2% | +28.6% | +0.8% | -0.5% | +40.2% | - |
| Other income | 0.19 | 0.23 | 0.04 | 0.02 | 0.07 | 0.04 |
| Total expenses | 8.48 | 7.41 | 5.40 | 4.99 | 5.32 | 3.72 |
| Employee cost | 2.60 | 2.38 | 1.92 | 1.55 | 1.38 | 0.92 |
| EBITDA | 1.00 | 0.82 | 1.00 | 1.36 | 1.06 | 0.83 |
| EBITDA margin | +10.6% | +10.0% | +15.6% | +21.4% | +16.6% | +18.2% |
| Depreciation | 0.51 | 0.45 | 0.44 | 0.45 | 0.38 | 0.25 |
| Interest | 0.07 | 0.06 | 0.09 | 0.07 | 0.06 | 0.08 |
| Profit before tax | 0.61 | 0.54 | 0.51 | 0.86 | 0.69 | 0.54 |
| Tax | 0.18 | 0.16 | 0.13 | 0.25 | 0.19 | 0.14 |
| Net profit | 0.43 | 0.29 | 0.37 | 0.61 | 0.50 | 0.37 |
| Net profit margin | +4.5% | +3.5% | +5.8% | +9.6% | +7.8% | +8.1% |
| EPS (₹) | 1.85 | 1.73 | 2.21 | 4.09 | 3.42 | 6.04 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 2.28 | 2.28 | 1.68 | 1.50 | 1.50 | 0.67 |
| Reserves & surplus | 6.97 | 6.55 | 1.87 | 0.88 | 0.35 | 0.72 |
| Shareholders' funds (net worth) | 9.25 | 8.83 | 3.55 | 2.38 | 1.85 | 1.39 |
| Secured loans | 0.36 | 0.00 | 0.53 | 0.59 | 0.64 | 0.48 |
| Unsecured loans | 0.00 | 0.00 | 0.34 | 0.44 | 0.25 | 0.06 |
| Total debt | 0.36 | 0.00 | 0.87 | 1.03 | 0.89 | 0.54 |
| Total liabilities | 9.86 | 9.03 | 4.61 | 5.02 | 2.85 | 2.02 |
| Assets | ||||||
| Gross block | 5.90 | 5.33 | 4.47 | 3.65 | 3.52 | 2.45 |
| Net block | 2.18 | 2.12 | 1.71 | 1.33 | 1.65 | 0.84 |
| Capital work in progress | 0.99 | 1.01 | 0.94 | 0.56 | 0.41 | 0.08 |
| Investments | 0.08 | 0.07 | 0.07 | 2.02 | 0.14 | 0.09 |
| Inventories | 0.73 | 0.53 | 0.28 | 0.14 | 0.16 | 0.09 |
| Sundry debtors | 1.85 | 1.54 | 0.60 | 0.49 | 0.36 | 0.56 |
| Cash & bank balances | 2.06 | 3.07 | 0.70 | 0.78 | 0.10 | 0.32 |
| Loans & advances | 2.72 | 2.32 | 1.12 | 0.55 | 0.76 | 0.66 |
| Total current assets | 7.36 | 7.46 | 2.70 | 1.96 | 1.38 | 1.63 |
| Total current liabilities | 1.05 | 1.81 | 1.00 | 1.01 | 0.83 | 0.71 |
| Net working capital | 6.31 | 5.65 | 1.70 | 0.95 | 0.55 | 0.92 |
| Total assets | 9.86 | 9.03 | 4.61 | 5.02 | 2.85 | 2.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 3.07 | 0.70 | 0.78 | 0.10 | 0.32 | 0.28 |
| Net cash from operating activities | (0.90) | (0.88) | (1.28) | 1.25 | 0.96 | 0.38 |
| Net cash from investing activities | (0.44) | (0.73) | 0.75 | (0.65) | (1.47) | 0.54 |
| Net cash from financing activities | 0.33 | 3.98 | 0.45 | 0.09 | 0.29 | (0.88) |
| Net change in cash | (1.01) | 2.37 | (0.08) | 0.68 | (0.22) | 0.04 |
| Closing cash | 2.06 | 3.07 | 0.70 | 0.78 | 0.10 | 0.32 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | +15.2% | +28.6% | +0.8% | -0.5% | +40.2% | - |
| EBITDA growth | +22.0% | -18.0% | -26.5% | +28.3% | +27.7% | - |
| PBT growth | +13.0% | +5.9% | -40.7% | +24.6% | +27.8% | +9997.0% |
| Net income growth | +48.3% | -21.6% | -39.3% | +22.0% | +35.1% | - |
| Revenue CAGR (3Y) | +14.3% | +8.9% | +12.0% | - | - | - |
| EBITDA CAGR (3Y) | -9.7% | -8.2% | +6.4% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +4.5% | +4.6% | +5.9% | +9.6% | +7.8% | +8.8% |
| Return on capital employed | +7.1% | +7.9% | +12.3% | +23.6% | +31.2% | +30.7% |
| Return on net worth | +4.7% | +4.9% | +12.5% | +28.8% | +31.5% | +28.8% |
| Debt / equity | 0.02 | 0.07 | 0.32 | 0.45 | 0.44 | 0.38 |
| Long-term debt / equity | 0.02 | 0.02 | 0.09 | 0.15 | 0.26 | 0.34 |
| Interest cover | 14.29 | 16.22 | 16.07 | 7.69 | 8.82 | 13.79 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 1.69 | 1.68 | 1.58 | 1.77 | 2.14 | 1.86 |
| Inventory turnover | 15.05 | 20.32 | 30.48 | 42.33 | 51.04 | 50.56 |
| Debtors turnover | 5.59 | 7.69 | 11.74 | 14.94 | 13.87 | 8.13 |
| EPS (₹) | 1.85 | 1.73 | 2.21 | 4.09 | 3.42 | 6.04 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 40.54 | 38.69 | 21.12 | 15.87 | 12.32 | 20.86 |
To see the full year-wise statements and ratios of Clinitech Laboratory Limited, buy the company report.
Board of directors of Clinitech Laboratory Limited
Clinitech Laboratory has 6 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ashutosh Jagdish Nayak Also directs: Sine Vibro LLP | Director | 31 Jan 2022 | 4 Years 9 Months | Current |
| Jagdish Umakant Nayak | Managing Director | 19 Mar 2010 | 16 Years 8 Months | Current |
| Jyoti Jagdish Nayak | Whole-Time Director | 19 Mar 2010 | 16 Years 8 Months | Current |
| Balu Laxman Kumbharkar Also directs: Waradavinayaka Private Limited | Director | 19 Jun 2023 | 3 Years 5 Months | Current |
| Ravikant Moreshwar Mhatre Also directs: Tristar Samriddhi Advisory LLP, Shanthala FMCG Products Limited, Shree Osfm E-Mobility Limited and 1 more | Director | 19 Jun 2023 | 3 Years 5 Months | Current |
| Smita Arjun Patil Also directs: Shanthala FMCG Products Limited | Director | 19 Jun 2023 | 3 Years 5 Months | Current |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 27 Aug 2026 | 101397094 | Others | ₹31.5 Lakh | Open | |
| 31 Jul 2026 | 101369826 | Others | ₹28 Lakh | Open | |
| 05 Feb 2026 | 101232728 | Others | ₹22.5 Lakh | Open | |
| 09 Apr 2025 | 101118096 | Others | ₹20 Lakh | Open | |
| 28 Dec 2021 | 100520583 | Others | ₹90 Lakh | Satisfied |
To see the full charge records of Clinitech Laboratory Limited, buy the company report.
Total charge records: 7 View all charges
Deals & funding
Clinitech Laboratory Limited has 17 deals on record (15 market trades, 1 ipo, 1 funding round), with disclosed funding of ₹68.4 Lakh; the latest was in April 2026.
Deals on record (5 of 17)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Aug 2025 | Market trade | ₹10.2 Lakh | Buyer: Bonanza Portfolio (Ifsc) Private Limited Seller: Bonanza Portfolio (Ifsc) Private Limited , an individual |
| Aug 2024 | Market trade | ₹12.7 Lakh | Seller: Multiplier Share and Stock Advisors Private Limited |
| Aug 2024 | Market trade | ₹13.4 Lakh | Seller: Multiplier Share and Stock Advisors Private Limited |
| Aug 2024 | Market trade | ₹26.6 Lakh | Buyer: Multiplier Share and Stock Advisors Private Limited |
| Aug 2024 | Market trade | ₹26.2 Lakh | Buyer: an individual Seller: Virtuous Capital Limited |
To see the full deal history of Clinitech Laboratory Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Clinitech Laboratory Limited has 1 court case on record: 1 filed by Clinitech Laboratory. All case is pending.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 1 | 0 | 1 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Thane, Maharashtra | Civil suit | Filed by the company against an individual | Pending |
To see the full case history of Clinitech Laboratory Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Clinitech Laboratory Limited has 4 MSME Form 1 returns on record between 2019 and 2024, listing 39 overdue payments to 9 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 9)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Analog Healthcare Private Limited | |||
| Laxmi Diagnostic | |||
| Lilac Insights Private Limited | |||
| Lifesys Biomedical |
To see the full MSME payment records of Clinitech Laboratory Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
No GST registration is on our record for Clinitech Laboratory Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Clinitech Laboratory Limited has 12 board changes on record since 2010: 6 appointments and 6 cessations. The latest: Ashutosh Jagdish Nayak ceased to be Director on 29 Sep 2023.
13 earlier events are in the company report.
Frequently asked questions
Clinitech Laboratory is an active public limited company based in Navi Mumbai, Maharashtra, India. The company works in diagnostic centers and pathology labs, within the healthcare industry. It was incorporated on 19 March 2010 (16+ years old) and is registered under CIN L85195MH2010PLC201078. Listed on BSE: 544220.
Clinitech Laboratory reported revenue of ₹9.49 Cr for FY 2025-26 (up 15.3% YoY) based on consolidated financials.
Clinitech Laboratory has 6 current directors:
- Jagdish Umakant Nayak - Managing Director
- Jyoti Jagdish Nayak - Whole-Time Director
- Ashutosh Jagdish Nayak - Director
- Balu Laxman Kumbharkar - Director
- Ravikant Moreshwar Mhatre - Director
- Smita Arjun Patil - Director
The latest financial statements of Clinitech Laboratory on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 23 September 2025. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Clinitech Laboratory is L85195MH2010PLC201078. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Clinitech Laboratory is a listed company as per MCA records. Its shares are listed on BSE (code: 544220).
Clinitech Laboratory has 1 court case on record: 1 filed by the company. 1 is pending.
Clinitech Laboratory was incorporated on 19 March 2010, making it 16+ years old. It is registered with the Registrar of Companies, Mumbai.
Clinitech Laboratory has 17 deals on record (15 market trades, 1 ipo, 1 funding round), with disclosed funding of ₹68.4 Lakh; the latest was in April 2026.
Ashutosh Jagdish Nayak ceased to be Director on 29 Sep 2023. Balu Laxman Kumbharkar ceased to be Additional Director on 29 Sep 2023. Jagdish Umakant Nayak ceased to be Director on 29 Sep 2023. Clinitech Laboratory has 12 board changes on record in total.
Yes, Clinitech Laboratory is registered as a small enterprise under Udyam registration (number: UDYAM-MH-33-0082699).

